Skip to content

Idexx Laboratories

NASDAQ: IDXX · USD

Idexx Laboratories financials

6 charts

Revenue

USD millions

$1,216.585M
Idexx Laboratories Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2010 Q2$281.482M; Change unavailable vs FY 2010 Q1
FY 2010 Q3$269.628M; −4.2% vs FY 2010 Q2
FY 2010 Q4$283.757M; +5.2% vs FY 2010 Q3
FY 2011 Q1$292.672M; +3.1% vs FY 2010 Q4
FY 2011 Q2$317.862M; +8.6% vs FY 2011 Q1
FY 2011 Q3$300.954M; −5.3% vs FY 2011 Q2
FY 2011 Q4$307.201M; +2.1% vs FY 2011 Q3
FY 2012 Q1$322.676M; +5.0% vs FY 2011 Q4
FY 2012 Q2$335.649M; +4.0% vs FY 2012 Q1
FY 2012 Q3$315.475M; −6.0% vs FY 2012 Q2
FY 2012 Q4$319.538M; +1.3% vs FY 2012 Q3
FY 2013 Q1$332.106M; +3.9% vs FY 2012 Q4
FY 2013 Q2$352.583M; +6.2% vs FY 2013 Q1
FY 2013 Q3$338.297M; −4.1% vs FY 2013 Q2
FY 2013 Q4$354.073M; +4.7% vs FY 2013 Q3
FY 2014 Q1$360.203M; +1.7% vs FY 2013 Q4
FY 2014 Q2$390.122M; +8.3% vs FY 2014 Q1
FY 2014 Q3$383.523M; −1.7% vs FY 2014 Q2
FY 2014 Q4$351.959M; −8.2% vs FY 2014 Q3
FY 2015 Q1$382.477M; +8.7% vs FY 2014 Q4
FY 2015 Q2$413.343M; +8.1% vs FY 2015 Q1
FY 2015 Q3$406.387M; −1.7% vs FY 2015 Q2
FY 2015 Q4$399.685M; −1.6% vs FY 2015 Q3
FY 2016 Q1$417.55M; +4.5% vs FY 2015 Q4
FY 2016 Q2$466.569M; +11.7% vs FY 2016 Q1
FY 2016 Q3$448.308M; −3.9% vs FY 2016 Q2
FY 2016 Q4$442.996M; −1.2% vs FY 2016 Q3
FY 2017 Q1$462.021M; +4.3% vs FY 2016 Q4
FY 2017 Q2$508.94M; +10.2% vs FY 2017 Q1
FY 2017 Q3$491.976M; −3.3% vs FY 2017 Q2
FY 2017 Q4$506.121M; +2.9% vs FY 2017 Q3
FY 2018 Q1$537.656M; +6.2% vs FY 2017 Q4
FY 2018 Q2$580.752M; +8.0% vs FY 2018 Q1
FY 2018 Q3$545.448M; −6.1% vs FY 2018 Q2
FY 2018 Q4$549.386M; +0.7% vs FY 2018 Q3
FY 2019 Q1$576.056M; +4.9% vs FY 2018 Q4
FY 2019 Q2$620.103M; +7.6% vs FY 2019 Q1
FY 2019 Q3$605.303M; −2.4% vs FY 2019 Q2
FY 2019 Q4$605.446M; 0.0% vs FY 2019 Q3
FY 2020 Q1$626.336M; +3.5% vs FY 2019 Q4
FY 2020 Q2$637.592M; +1.8% vs FY 2020 Q1
FY 2020 Q3$721.789M; +13.2% vs FY 2020 Q2
FY 2020 Q4$720.938M; −0.1% vs FY 2020 Q3
FY 2021 Q1$777.707M; +7.9% vs FY 2020 Q4
FY 2021 Q2$826.142M; +6.2% vs FY 2021 Q1
FY 2021 Q3$810.421M; −1.9% vs FY 2021 Q2
FY 2021 Q4$801.09M; −1.2% vs FY 2021 Q3
FY 2022 Q1$836.549M; +4.4% vs FY 2021 Q4
FY 2022 Q2$860.546M; +2.9% vs FY 2022 Q1
FY 2022 Q3$841.661M; −2.2% vs FY 2022 Q2
FY 2022 Q4$828.568M; −1.6% vs FY 2022 Q3
FY 2023 Q1$900.195M; +8.6% vs FY 2022 Q4
FY 2023 Q2$943.63M; +4.8% vs FY 2023 Q1
FY 2023 Q3$915.527M; −3.0% vs FY 2023 Q2
FY 2023 Q4$901.601M; −1.5% vs FY 2023 Q3
FY 2024 Q1$964.095M; +6.9% vs FY 2023 Q4
FY 2024 Q2$1,003.578M; +4.1% vs FY 2024 Q1
FY 2024 Q3$975.543M; −2.8% vs FY 2024 Q2
FY 2024 Q4$954.288M; −2.2% vs FY 2024 Q3
FY 2025 Q1$998.427M; +4.6% vs FY 2024 Q4
FY 2025 Q2$1,109.457M; +11.1% vs FY 2025 Q1
FY 2025 Q3$1,105.239M; −0.4% vs FY 2025 Q2
FY 2025 Q4$1,090.579M; −1.3% vs FY 2025 Q3
FY 2026 Q1$1,140.82M; +4.6% vs FY 2025 Q4
FY 2026 Q2$1,216.585M; +6.6% vs FY 2026 Q1
Jun 30, 2010 through Sep 25, 2026

Free cash flow

USD millions

$322.516M
Idexx Laboratories Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2010 Q2$46.916M; Change unavailable vs FY 2010 Q1
FY 2010 Q3$43.689M; −6.9% vs FY 2010 Q2
FY 2010 Q4$38.588M; −11.7% vs FY 2010 Q3
FY 2011 Q1$15.643M; −59.5% vs FY 2010 Q4
FY 2011 Q2$46.494M; +197.2% vs FY 2011 Q1
FY 2011 Q3$61.454M; +32.2% vs FY 2011 Q2
FY 2011 Q4$44.645M; −27.4% vs FY 2011 Q3
FY 2012 Q1$5.738M; −87.1% vs FY 2011 Q4
FY 2012 Q2$48.761M; +749.8% vs FY 2012 Q1
FY 2012 Q3$55.759M; +14.4% vs FY 2012 Q2
FY 2012 Q4$54.532M; −2.2% vs FY 2012 Q3
FY 2013 Q1$0.923M; −98.3% vs FY 2012 Q4
FY 2013 Q2$55.38M; +5900.0% vs FY 2013 Q1
FY 2013 Q3$62.819M; +13.4% vs FY 2013 Q2
FY 2013 Q4$49.262M; −21.6% vs FY 2013 Q3
FY 2014 Q1$22.22M; −54.9% vs FY 2013 Q4
FY 2014 Q2$67.65M; +204.5% vs FY 2014 Q1
FY 2014 Q3$76.169M; +12.6% vs FY 2014 Q2
FY 2014 Q4$9.284M; −87.8% vs FY 2014 Q3
FY 2015 Q1$-37.661M; −505.7% vs FY 2014 Q4
FY 2015 Q2$56.31M; +249.5% vs FY 2015 Q1
FY 2015 Q3$56.302M; 0.0% vs FY 2015 Q2
FY 2015 Q4$58.492M; +3.9% vs FY 2015 Q3
FY 2016 Q1$1.32M; −97.7% vs FY 2015 Q4
FY 2016 Q2$94.953M; +7093.4% vs FY 2016 Q1
FY 2016 Q3$88.227M; −7.1% vs FY 2016 Q2
FY 2016 Q4$85.284M; −3.3% vs FY 2016 Q3
FY 2017 Q1$7.627M; −91.1% vs FY 2016 Q4
FY 2017 Q2$95.273M; +1149.2% vs FY 2017 Q1
FY 2017 Q3$94.88M; −0.4% vs FY 2017 Q2
FY 2017 Q4$101.112M; +6.6% vs FY 2017 Q3
FY 2018 Q1$11.172M; −89.0% vs FY 2017 Q4
FY 2018 Q2$91.179M; +716.1% vs FY 2018 Q1
FY 2018 Q3$79.443M; −12.9% vs FY 2018 Q2
FY 2018 Q4$102.539M; +29.1% vs FY 2018 Q3
FY 2019 Q1$-3.828M; −103.7% vs FY 2018 Q4
FY 2019 Q2$103.321M; +2799.1% vs FY 2019 Q1
FY 2019 Q3$95.194M; −7.9% vs FY 2019 Q2
FY 2019 Q4$109.502M; +15.0% vs FY 2019 Q3
FY 2020 Q1$-21.131M; −119.3% vs FY 2019 Q4
FY 2020 Q2$183.586M; +968.8% vs FY 2020 Q1
FY 2020 Q3$173.906M; −5.3% vs FY 2020 Q2
FY 2020 Q4$204.744M; +17.7% vs FY 2020 Q3
FY 2021 Q1$104.259M; −49.1% vs FY 2020 Q4
FY 2021 Q2$211.374M; +102.7% vs FY 2021 Q1
FY 2021 Q3$142.188M; −32.7% vs FY 2021 Q2
FY 2021 Q4$178.176M; +25.3% vs FY 2021 Q3
FY 2022 Q1$82.868M; −53.5% vs FY 2021 Q4
FY 2022 Q2$35.764M; −56.8% vs FY 2022 Q1
FY 2022 Q3$151.315M; +323.1% vs FY 2022 Q2
FY 2022 Q4$124.199M; −17.9% vs FY 2022 Q3
FY 2023 Q1$144.401M; +16.3% vs FY 2022 Q4
FY 2023 Q2$172.844M; +19.7% vs FY 2023 Q1
FY 2023 Q3$238.339M; +37.9% vs FY 2023 Q2
FY 2023 Q4$217.295M; −8.8% vs FY 2023 Q3
FY 2024 Q1$168.312M; −22.5% vs FY 2023 Q4
FY 2024 Q2$215.007M; +27.7% vs FY 2024 Q1
FY 2024 Q3$191.99M; −10.7% vs FY 2024 Q2
FY 2024 Q4$232.77M; +21.2% vs FY 2024 Q3
FY 2025 Q1$207.936M; −10.7% vs FY 2024 Q4
FY 2025 Q2$151.641M; −27.1% vs FY 2025 Q1
FY 2025 Q3$371.226M; +144.8% vs FY 2025 Q2
FY 2025 Q4$326.326M; −12.1% vs FY 2025 Q3
FY 2026 Q1$234.264M; −28.2% vs FY 2025 Q4
FY 2026 Q2$322.516M; +37.7% vs FY 2026 Q1

Net margin

%

27.82%
Idexx Laboratories Net margin. Reported fiscal history.
Fiscal period%
FY 2010 Q213.21%
FY 2010 Q312.87%
FY 2010 Q412.82%
FY 2011 Q112.51%
FY 2011 Q215.31%
FY 2011 Q312.79%
FY 2011 Q412.37%
FY 2012 Q112.63%
FY 2012 Q215.29%
FY 2012 Q313.58%
FY 2012 Q413.57%
FY 2013 Q113.51%
FY 2013 Q215.31%
FY 2013 Q313.51%
FY 2013 Q412.22%
FY 2014 Q112.93%
FY 2014 Q214.67%
FY 2014 Q313.6%
FY 2014 Q47.38%
FY 2015 Q112.18%
FY 2015 Q213.77%
FY 2015 Q310.88%
FY 2015 Q411.1%
FY 2016 Q111.02%
FY 2016 Q214.4%
FY 2016 Q312.59%
FY 2016 Q411.82%
FY 2017 Q114.94%
FY 2017 Q216.77%
FY 2017 Q314.33%
FY 2017 Q47.56%
FY 2018 Q116.64%
FY 2018 Q218.72%
FY 2018 Q317.1%
FY 2018 Q415.59%
FY 2019 Q117.82%
FY 2019 Q220.27%
FY 2019 Q317.98%
FY 2019 Q414.95%
FY 2020 Q117.85%
FY 2020 Q223.36%
FY 2020 Q320.26%
FY 2020 Q424.24%
FY 2021 Q126.26%
FY 2021 Q224.52%
FY 2021 Q321.62%
FY 2021 Q420.32%
FY 2022 Q123.19%
FY 2022 Q215.34%
FY 2022 Q321.5%
FY 2022 Q420.78%
FY 2023 Q123.78%
FY 2023 Q223.76%
FY 2023 Q323.18%
FY 2023 Q421.58%
FY 2024 Q124.44%
FY 2024 Q220.26%
FY 2024 Q323.87%
FY 2024 Q422.65%
FY 2025 Q124.31%
FY 2025 Q226.5%
FY 2025 Q324.85%
FY 2025 Q422.76%
FY 2026 Q124.41%
FY 2026 Q227.82%

P/E

× · TTM · Daily

36.14×
Idexx Laboratories P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2013-02-2828.84×2012-12-31
2013-03-2828.93×2012-12-31
2013-04-3026.76×2013-03-31
2013-05-3125.08×2013-03-31
2013-06-2827.29×2013-03-31
2013-07-3128.8×2013-06-30
2013-08-3027.57×2013-06-30
2013-09-3029.29×2013-06-30
2013-10-3130.56×2013-09-30
2013-11-2929.51×2013-09-30
2013-12-3130.14×2013-09-30
2014-01-3132.38×2013-09-30
2014-02-2835.38×2013-12-31
2014-03-3134.12×2013-12-31
2014-04-3034.92×2014-03-31
2014-05-3035.48×2014-03-31
2014-06-3036.89×2014-03-31
2014-07-3133.45×2014-06-30
2014-08-2933.31×2014-06-30
2014-09-3031.66×2014-06-30
2014-10-3135.84×2014-09-30
2014-11-2837.79×2014-09-30
2014-12-3137.51×2014-09-30
2015-01-3040.08×2014-09-30
2015-02-2741.78×2014-12-31
2015-03-3141.16×2014-12-31
2015-04-3032.92×2015-03-31
2015-05-2935.6×2015-03-31
2015-06-3033.68×2015-03-31
2015-07-3137.77×2015-06-30
2015-08-3137.11×2015-06-30
2015-09-3038.56×2015-06-30
2015-10-3035.63×2015-06-30
2015-11-3036.78×2015-06-30
2015-12-3137.87×2015-06-30
2016-01-2936.42×2015-06-30
2016-02-2934.98×2015-12-31
2016-03-3137.44×2015-12-31
2016-04-2940.33×2015-12-31
2016-05-3141.87×2015-12-31
2016-06-3044.4×2015-12-31
2016-07-2944.84×2015-12-31
2016-08-3150.71×2016-06-30
2016-09-3050.73×2016-06-30
2016-10-3148.22×2016-06-30
2016-11-3050.1×2016-09-30
2016-12-3049.94×2016-09-30
2017-01-3152.09×2016-09-30
2017-02-2859.18×2016-12-31
2017-03-3163.12×2016-12-31
2017-04-2868.48×2016-12-31
2017-05-3161.84×2017-03-31
2017-06-3059.28×2017-03-31
2017-07-3161.13×2017-03-31
2017-08-3153.08×2017-06-30
2017-09-2953.1×2017-06-30
2017-10-3156.74×2017-06-30
2017-11-3050.35×2017-09-30
2017-12-2950.34×2017-09-30
2018-01-3160.21×2017-09-30
2018-02-2863.37×2017-12-31
2018-03-2964.78×2017-12-31
2018-04-3065.83×2017-12-31
2018-05-3165.31×2018-03-31
2018-06-2968.36×2018-03-31
2018-07-3176.82×2018-03-31
2018-08-3173.33×2018-06-30
2018-09-2872.07×2018-06-30
2018-10-3161.23×2018-06-30
2018-11-3054.67×2018-09-30
2018-12-3149.91×2018-09-30
2019-01-3157.09×2018-09-30
2019-02-2849.16×2018-12-31
2019-03-2952.09×2018-12-31
2019-04-3054.04×2018-12-31
2019-05-3156.03×2019-03-31
2019-06-2861.77×2019-03-31
2019-07-3163.27×2019-03-31
2019-08-3062.33×2019-06-30
2019-09-3058.5×2019-06-30
2019-10-3161.31×2019-06-30
2019-11-2952.16×2019-09-30
2019-12-3154.14×2019-09-30
2020-01-3156.19×2019-09-30
2020-02-2852.76×2019-09-30
2020-03-3150.22×2019-09-30
2020-04-3057.55×2019-09-30
2020-05-2961.3×2020-03-31
2020-06-3065.53×2020-03-31
2020-07-3178.94×2020-03-31
2020-08-3173.44×2020-06-30
2020-09-3073.82×2020-06-30
2020-10-3074.03×2020-09-30
2020-11-3080.33×2020-09-30
2020-12-3187.11×2020-09-30
2021-01-2983.41×2020-09-30
2021-02-2677.77×2020-12-31
2021-03-3173.16×2020-12-31
2021-04-3082.08×2020-12-31
2021-05-2871.95×2021-03-31
2021-06-3081.42×2021-03-31
2021-07-3087.47×2021-03-31
2021-08-3180.21×2021-06-30
2021-09-3074.04×2021-06-30
2021-10-2979.31×2021-06-30
2021-11-3069.5×2021-09-30
2021-12-3175.26×2021-09-30
2022-01-3157.99×2021-09-30
2022-02-2861.58×2021-12-31
2022-03-3163.28×2021-12-31
2022-04-2949.79×2021-12-31
2022-05-3145.62×2022-03-31
2022-06-3040.85×2022-03-31
2022-07-2946.5×2022-03-31
2022-08-3144.43×2022-06-30
2022-09-3041.64×2022-06-30
2022-10-3145.97×2022-06-30
2022-11-3053.49×2022-09-30
2022-12-3051.24×2022-09-30
2023-01-3160.35×2022-09-30
2023-02-2858.42×2022-12-31
2023-03-3161.74×2022-12-31
2023-04-2860.76×2022-12-31
2023-05-3155.81×2023-03-31
2023-06-3060.31×2023-03-31
2023-07-3166.61×2023-03-31
2023-08-3154.27×2023-06-30
2023-09-2946.4×2023-06-30
2023-10-3142.39×2023-06-30
2023-11-3047.56×2023-09-30
2023-12-2956.67×2023-09-30
2024-01-3152.58×2023-09-30
2024-02-2957.14×2023-12-31
2024-03-2853.63×2023-12-31
2024-04-3048.95×2023-12-31
2024-05-3148.15×2024-03-31
2024-06-2847.2×2024-03-31
2024-07-3146.13×2024-03-31
2024-08-3047.47×2024-06-30
2024-09-3049.82×2024-06-30
2024-10-3140.13×2024-06-30
2024-11-2940.44×2024-09-30
2024-12-3139.64×2024-09-30
2025-01-3140.47×2024-09-30
2025-02-2840.64×2024-12-31
2025-03-3139.05×2024-12-31
2025-04-3040.23×2024-12-31
2025-05-3046.99×2025-03-31
2025-06-3049.09×2025-03-31
2025-07-3148.91×2025-03-31
2025-08-2953.17×2025-06-30
2025-09-3052.5×2025-06-30
2025-10-3151.73×2025-06-30
2025-11-2859.12×2025-09-30
2025-12-3153.12×2025-09-30
2026-01-3052.65×2025-09-30
2026-02-2749.89×2025-12-31
2026-03-3142.69×2025-12-31
2026-04-3042.6×2025-12-31
2026-05-2941.25×2026-03-31
2026-06-3038.53×2026-03-31
2026-07-3140.92×2026-03-31
2026-08-3138.74×2026-06-30
2026-09-2536.14×2026-06-30
Mean 51.14×Median 50.73×29% below median

ROIC

% · Annual / TTM

63.35%
Idexx Laboratories ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q4—
FY 2011 Q1—
FY 2011 Q2—
FY 2011 Q3—
FY 2011 Q4—
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q446.42%
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q447.26%
FY 2014 Q1—
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q471.72%
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q479.74%
FY 2016 Q1—
FY 2016 Q2—
FY 2016 Q3—
FY 2016 Q467.63%
FY 2017 Q1—
FY 2017 Q2—
FY 2017 Q3—
FY 2017 Q482.05%
FY 2018 Q1—
FY 2018 Q2—
FY 2018 Q3—
FY 2018 Q497.08%
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q472.16%
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q462.84%
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q359.45%
FY 2021 Q460.25%
FY 2022 Q161.5%
FY 2022 Q254.3%
FY 2022 Q353.51%
FY 2022 Q453.34%
FY 2023 Q154.21%
FY 2023 Q258.27%
FY 2023 Q359.71%
FY 2023 Q458.36%
FY 2024 Q152.72%
FY 2024 Q247.83%
FY 2024 Q348.05%
FY 2024 Q449.42%
FY 2025 Q148.36%
FY 2025 Q254.58%
FY 2025 Q355.29%
FY 2025 Q457.27%
FY 2026 Q160.61%
FY 2026 Q263.35%

Capital allocation

% of tracked cash uses

$371.45M
Idexx Laboratories capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2010 Q225.64% · $8.964MUnavailable74.36% · $25.996MUnavailableUnavailable100% · $34.96M
FY 2010 Q325.11% · $11.209MUnavailable74.89% · $33.433MUnavailableUnavailable100% · $44.642M
FY 2010 Q428.35% · $10.262MUnavailable71.65% · $25.933MUnavailableUnavailable100% · $36.195M
FY 2011 Q119.34% · $9.575MUnavailable80.66% · $39.94MUnavailableUnavailable100% · $49.515M
FY 2011 Q222.11% · $16.598MUnavailable77.89% · $58.479MUnavailableUnavailable100% · $75.077M
FY 2011 Q316.91% · $13.754MUnavailable83.09% · $67.597MUnavailableUnavailable100% · $81.351M
FY 2011 Q48.58% · $12.537M30.21% · $44.157M61.22% · $89.489MUnavailableUnavailable100% · $146.183M
FY 2012 Q125.48% · $9.446MUnavailable74.52% · $27.63MUnavailableUnavailable100% · $37.076M
FY 2012 Q235.18% · $14.855MUnavailable64.82% · $27.376MUnavailableUnavailable100% · $42.231M
FY 2012 Q334.37% · $18.929MUnavailable65.63% · $36.146MUnavailableUnavailable100% · $55.075M
FY 2012 Q435.13% · $22.262MUnavailable64.87% · $41.116MUnavailableUnavailable100% · $63.378M
FY 2013 Q123.65% · $19.761MUnavailable76.35% · $63.778MUnavailableUnavailable100% · $83.539M
FY 2013 Q214.38% · $23.938MUnavailable85.62% · $142.557MUnavailableUnavailable100% · $166.495M
FY 2013 Q318.09% · $16.908MUnavailable81.91% · $76.575MUnavailableUnavailable100% · $93.483M
FY 2013 Q416.56% · $17.005M0.8% · $0.822M82.64% · $84.851MUnavailableUnavailable100% · $102.678M
FY 2014 Q113.66% · $11.298M1.4% · $1.161M84.94% · $70.279MUnavailableUnavailable100% · $82.738M
FY 2014 Q210.05% · $14.112M0% · $0M89.95% · $126.347MUnavailableUnavailable100% · $140.459M
FY 2014 Q35.78% · $17.094M2.15% · $6.355M92.07% · $272.342MUnavailableUnavailable100% · $295.791M
FY 2014 Q49.75% · $18.019M9.52% · $17.599M80.73% · $149.19MUnavailableUnavailable100% · $184.808M
FY 2015 Q114.66% · $23.017M0.24% · $0.383M85.1% · $133.647MUnavailableUnavailable100% · $157.047M
FY 2015 Q221.63% · $23.856M0% · $0M78.37% · $86.45MUnavailableUnavailable100% · $110.306M
FY 2015 Q317.58% · $20.644M6.66% · $7.817M75.76% · $88.96MUnavailableUnavailable100% · $117.421M
FY 2015 Q413.95% · $15.404M1.9% · $2.102M84.15% · $92.924MUnavailableUnavailable100% · $110.43M
FY 2016 Q129.06% · $21.906MUnavailable70.94% · $53.48MUnavailableUnavailable100% · $75.386M
FY 2016 Q240.91% · $15.962MUnavailable59.09% · $23.056MUnavailableUnavailable100% · $39.018M
FY 2016 Q344.58% · $12.088MUnavailable55.42% · $15.026MUnavailableUnavailable100% · $27.114M
FY 2016 Q46.52% · $14.831MUnavailable93.48% · $212.524MUnavailableUnavailable100% · $227.355M
FY 2017 Q126.3% · $23.647M2.61% · $2.349M71.09% · $63.91MUnavailableUnavailable100% · $89.906M
FY 2017 Q211.13% · $14.919M9.09% · $12.18M79.77% · $106.888MUnavailableUnavailable100% · $133.987M
FY 2017 Q321.44% · $15.804M0% · $0M78.56% · $57.895MUnavailableUnavailable100% · $73.699M
FY 2017 Q427.07% · $20.014M0.07% · $0.05M72.86% · $53.872MUnavailableUnavailable100% · $73.936M
FY 2018 Q122.13% · $23.726MUnavailable77.87% · $83.487MUnavailableUnavailable100% · $107.213M
FY 2018 Q220.63% · $27.651MUnavailable79.37% · $106.397MUnavailableUnavailable100% · $134.048M
FY 2018 Q324.5% · $31.265M17.63% · $22.5M57.86% · $73.828MUnavailableUnavailable100% · $127.593M
FY 2018 Q423.87% · $33.109M0% · $0M76.13% · $105.607MUnavailableUnavailable100% · $138.716M
FY 2019 Q141.3% · $38.206MUnavailable58.7% · $54.302MUnavailableUnavailable100% · $92.508M
FY 2019 Q262.01% · $33.781MUnavailable37.99% · $20.692MUnavailableUnavailable100% · $54.473M
FY 2019 Q330.13% · $37.071MUnavailable69.87% · $85.975MUnavailableUnavailable100% · $123.046M
FY 2019 Q424.6% · $45.911MUnavailable75.4% · $140.689MUnavailableUnavailable100% · $186.6M
FY 2020 Q121.14% · $49.002M0% · $0M78.86% · $182.815MUnavailableUnavailable100% · $231.817M
FY 2020 Q2100% · $24.556M0% · $0M0% · $0MUnavailableUnavailable100% · $24.556M
FY 2020 Q3100% · $19.21M0% · $0M0% · $0MUnavailableUnavailable100% · $19.21M
FY 2020 Q490.44% · $14.19M9.56% · $1.5M0% · $0MUnavailableUnavailable100% · $15.69M
FY 2021 Q112.86% · $20.163M2.82% · $4.424M84.32% · $132.262MUnavailableUnavailable100% · $156.849M
FY 2021 Q26.22% · $22.581M41.87% · $152.082M51.91% · $188.525MUnavailableUnavailable100% · $363.188M
FY 2021 Q319.5% · $45.017M2.02% · $4.66M78.49% · $181.234MUnavailableUnavailable100% · $230.911M
FY 2021 Q411.01% · $31.788M4.24% · $12.252M84.75% · $244.756MUnavailableUnavailable100% · $288.796M
FY 2022 Q110.68% · $31.838M0% · $0M89.32% · $266.295MUnavailableUnavailable100% · $298.133M
FY 2022 Q28.93% · $30.086M0% · $0M91.07% · $306.765MUnavailableUnavailable100% · $336.851M
FY 2022 Q316.99% · $37.685M5.19% · $11.512M77.82% · $172.631MUnavailableUnavailable100% · $221.828M
FY 2022 Q439.94% · $49.229M0% · $0M60.06% · $74.02MUnavailableUnavailable100% · $123.249M
FY 2023 Q1100% · $39.511M0% · $0M0% · $0MUnavailableUnavailable100% · $39.511M
FY 2023 Q2100% · $27.47M0% · $0M0% · $0MUnavailableUnavailable100% · $27.47M
FY 2023 Q349.29% · $34.094M0% · $0M50.71% · $35.07MUnavailableUnavailable100% · $69.164M
FY 2023 Q446.91% · $32.556M0% · $0M53.09% · $36.85MUnavailableUnavailable100% · $69.406M
FY 2024 Q111.55% · $30.273M29.39% · $77M59.06% · $154.764MUnavailableUnavailable100% · $262.037M
FY 2024 Q213.38% · $33.305M0% · $0M86.62% · $215.521MUnavailableUnavailable100% · $248.826M
FY 2024 Q311.29% · $28.089MUnavailable88.71% · $220.757MUnavailableUnavailable100% · $248.846M
FY 2024 Q410.63% · $29.255M0% · $0M89.37% · $245.992MUnavailableUnavailable100% · $275.247M
FY 2025 Q16.97% · $30.026M0% · $0M93.03% · $400.89MUnavailableUnavailable100% · $430.916M
FY 2025 Q29.16% · $34.102M0% · $0M90.84% · $338.105MUnavailableUnavailable100% · $372.207M
FY 2025 Q311.47% · $31.114M0% · $0M88.53% · $240.195MUnavailableUnavailable100% · $271.309M
FY 2025 Q411.02% · $29.434M0% · $0M88.98% · $237.774MUnavailableUnavailable100% · $267.208M
FY 2026 Q18.35% · $31.984MUnavailable91.65% · $351.036MUnavailableUnavailable100% · $383.02M
FY 2026 Q26.64% · $24.646MUnavailable93.36% · $346.804MUnavailableUnavailable100% · $371.45M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Idexx Laboratories.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources